Esperion Therapeutics (ESPR) said Thursday the US Food and Drug Administration has confirmed that it has enough data to proceed with phase 3 studies of bempedoic acid as a monotherapy and in combination with ezetimibe in children with heterozygous and homozygous familial hypercholesterolemia.
The company said it plans to begin phase 3 trials this year and apply for an additional six-month patent extension through June 2031.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。